Literature DB >> 26317490

Human papillomavirus capsids preferentially bind and infect tumor cells.

Rhonda C Kines1, Rebecca J Cerio2, Jeffrey N Roberts2, Cynthia D Thompson2, Elisabet de Los Pinos1, Douglas R Lowy2, John T Schiller2.   

Abstract

We previously determined that human papillomavirus (HPV) virus-like particles (VLPs) and pseudovirions (PsV) did not, respectively, bind to or infect intact epithelium of the cervicovaginal tract. However, they strongly bound heparan sulfate proteoglycans (HSPG) on the basement membrane of disrupted epithelium and infected the keratinocytes that subsequently entered the disrupted site. We here report that HPV capsids (VLP and PsV) have the same restricted tropism for a wide variety of disrupted epithelial and mesothelial tissues, whereas intact tissues remain resistant to binding. However, the HPV capsids directly bind and infect most tumor-derived cell lines in vitro and have analogous tumor-specific properties in vivo, after local or intravenous injection, using orthotopic models for human ovarian and lung cancer, respectively. The pseudovirions also specifically infected implanted primary human ovarian tumors. Heparin and ι-carrageenan blocked binding and infection of all tumor lines tested, implying that tumor cell binding is HSPG-dependent. A survey using a panel of modified heparins indicates that N-sulfation and, to a lesser degree, O-6 sulfation of the surface HSPG on the tumors are important for HPV binding. Therefore, it appears that tumor cells consistently evolve HSPG modification patterns that mimic the pattern normally found on the basement membrane but not on the apical surfaces of normal epithelial or mesothelial cells. Consequently, appropriately modified HPV VLPs and/or PsV could be useful reagents to detect and potentially treat a remarkably broad spectrum of cancers.
© 2015 UICC.

Entities:  

Keywords:  heparan sulfate proteoglycans; human papillomavirus; tumor tropism

Mesh:

Substances:

Year:  2015        PMID: 26317490      PMCID: PMC4715788          DOI: 10.1002/ijc.29823

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  44 in total

1.  Tumor cell surface heparan sulfate as cryptic promoters or inhibitors of tumor growth and metastasis.

Authors:  Dongfang Liu; Zachary Shriver; Ganesh Venkataraman; Yosuf El Shabrawi; Ram Sasisekharan
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-22       Impact factor: 11.205

2.  Physical interaction of human papillomavirus virus-like particles with immune cells.

Authors:  D M Da Silva; M P Velders; J D Nieland; J T Schiller; B J Nickoloff; W M Kast
Journal:  Int Immunol       Date:  2001-05       Impact factor: 4.823

3.  Colorectal papillomavirus infection in patients with colorectal cancer.

Authors:  Sohrab Bodaghi; Koji Yamanegi; Shu-Yuan Xiao; Maria Da Costa; Joel M Palefsky; Zhi-Ming Zheng
Journal:  Clin Cancer Res       Date:  2005-04-15       Impact factor: 12.531

4.  Intravaginal immunization with HPV vectors induces tissue-resident CD8+ T cell responses.

Authors:  Nicolas Çuburu; Barney S Graham; Christopher B Buck; Rhonda C Kines; Yuk-Ying S Pang; Patricia M Day; Douglas R Lowy; John T Schiller
Journal:  J Clin Invest       Date:  2012-11-12       Impact factor: 14.808

Review 5.  Heparan sulfate proteoglycans on the cell surface: versatile coordinators of cellular functions.

Authors:  S Tumova; A Woods; J R Couchman
Journal:  Int J Biochem Cell Biol       Date:  2000-03       Impact factor: 5.085

Review 6.  The sweet and sour of cancer: glycans as novel therapeutic targets.

Authors:  Mark M Fuster; Jeffrey D Esko
Journal:  Nat Rev Cancer       Date:  2005-07       Impact factor: 60.716

7.  The initial steps leading to papillomavirus infection occur on the basement membrane prior to cell surface binding.

Authors:  Rhonda C Kines; Cynthia D Thompson; Douglas R Lowy; John T Schiller; Patricia M Day
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-17       Impact factor: 11.205

8.  A target cell-specific activatable fluorescence probe for in vivo molecular imaging of cancer based on a self-quenched avidin-rhodamine conjugate.

Authors:  Yukihiro Hama; Yasuteru Urano; Yoshinori Koyama; Mako Kamiya; Marcelino Bernardo; Ronald S Paik; In Soo Shin; Chang H Paik; Peter L Choyke; Hisataka Kobayashi
Journal:  Cancer Res       Date:  2007-03-15       Impact factor: 12.701

9.  Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan.

Authors:  Jeffrey N Roberts; Christopher B Buck; Cynthia D Thompson; Rhonda Kines; Marcelino Bernardo; Peter L Choyke; Douglas R Lowy; John T Schiller
Journal:  Nat Med       Date:  2007-07-01       Impact factor: 53.440

10.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

View more
  14 in total

Review 1.  Papillomavirus assembly: An overview and perspectives.

Authors:  Carla Cerqueira; John T Schiller
Journal:  Virus Res       Date:  2016-11-10       Impact factor: 3.303

2.  Chondroitin Sulfate Proteoglycans Are De Facto Cellular Receptors for Human Papillomavirus 16 under High Serum Conditions.

Authors:  Nathan R Fons; Rhonda C Kines; Cynthia D Thompson; Patricia M Day; Douglas R Lowy; John T Schiller
Journal:  J Virol       Date:  2022-03-14       Impact factor: 6.549

3.  An Infrared Dye-Conjugated Virus-like Particle for the Treatment of Primary Uveal Melanoma.

Authors:  Rhonda C Kines; Isabella Varsavsky; Sanghamitra Choudhary; Debaditya Bhattacharya; Sean Spring; Roger McLaughlin; Shin J Kang; Hans E Grossniklaus; Demetrios Vavvas; Stephen Monks; John R MacDougall; Elisabet de Los Pinos; John T Schiller
Journal:  Mol Cancer Ther       Date:  2017-12-14       Impact factor: 6.261

4.  Virus-Like Particle-Drug Conjugates Induce Protective, Long-lasting Adaptive Antitumor Immunity in the Absence of Specifically Targeted Tumor Antigens.

Authors:  Rhonda C Kines; Cynthia D Thompson; Sean Spring; Zhenyu Li; Elisabet de Los Pinos; Stephen Monks; John T Schiller
Journal:  Cancer Immunol Res       Date:  2021-04-14       Impact factor: 12.020

5.  Efficient Production of Papillomavirus Gene Delivery Vectors in Defined In Vitro Reactions.

Authors:  Carla Cerqueira; Cynthia D Thompson; Patricia M Day; Yuk-Ying S Pang; Douglas R Lowy; John T Schiller
Journal:  Mol Ther Methods Clin Dev       Date:  2017-04-19       Impact factor: 6.698

6.  Papillomaviruses: a systematic review.

Authors:  Rodrigo Pinheiro Araldi; Suely Muro Reis Assaf; Rodrigo Franco de Carvalho; Márcio Augusto Caldas Rocha de Carvalho; Jacqueline Mazzuchelli de Souza; Roberta Fiusa Magnelli; Diego Grando Módolo; Franco Peppino Roperto; Rita de Cassia Stocco; Willy Beçak
Journal:  Genet Mol Biol       Date:  2017-02-16       Impact factor: 1.771

7.  Papilloma-pseudovirus eradicates intestinal tumours and triples the lifespan of ApcMin/+ mice.

Authors:  Zhenyu Zhong; Yougang Zhai; Ping Bu; Shivanee Shah; Liang Qiao
Journal:  Nat Commun       Date:  2017-04-11       Impact factor: 14.919

Review 8.  Uveal melanoma: epidemiology, etiology, and treatment of primary disease.

Authors:  Benjamin A Krantz; Nikita Dave; Kimberly M Komatsubara; Brian P Marr; Richard D Carvajal
Journal:  Clin Ophthalmol       Date:  2017-01-31

9.  Case of Paradoxical Cultural Sensitivity: Mixed Method Study of Web-Based Health Informational Materials About the Human Papillomavirus Vaccine in Israel.

Authors:  Nour Abed Elhadi Shahbari; Anat Gesser-Edelsburg; Gustavo S Mesch
Journal:  J Med Internet Res       Date:  2019-05-17       Impact factor: 5.428

10.  Immunogenic Human Papillomavirus Pseudovirus-Mediated Suicide-Gene Therapy for Bladder Cancer.

Authors:  Rim Hojeij; Sonia Domingos-Pereira; Marianne Nkosi; Dalila Gharbi; Laurent Derré; John T Schiller; Patrice Jichlinski; Denise Nardelli-Haefliger
Journal:  Int J Mol Sci       Date:  2016-07-14       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.